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Diffuse large B cell lymphoma (DLBCL) is the 
most commonly diagnosed lymphoma in adults. 
It may either arise de novo at nodal or extra-
nodal sites or as a consequence of malignant 
transformation of indolent lymphomas or leuke-
mias such as follicular lymphoma (FL), chronic 
lymphocytic leukemia (CLL), and marginal zone 
lymphoma (MZL; Schneider et al., 2011; Shaffer 
et al., 2012; Pasqualucci and Dalla-Favera, 2014). 
DLBCL represents a heterogeneous disease, 
with molecular subtypes being characterized 
by distinct gene expression profiles, specific 
sets of somatic mutations, and differentially ac-
tive intracellular signaling pathways (Roschewski 
et al., 2014). Three subtypes of DLBCL can be 
distinguished based on the presumed normal 
B cell counterpart, with activated B cell–like 
DLBCL (ABC-DLBCL) resembling the post–
germinal center (GC) plasmablast, GC B cell–
like DLBCL (GCB-DLBCL) deriving from 
GC B cells, and primary mediastinal B cell 
lymphoma (PMBL) arising in the thymus from 
a rare subset of thymic B cells (Alizadeh et al., 
2000; Rosenwald et al., 2003). The three sub-
types of DLBCL differ not only in their patho-
genesis, but also in their cure and survival rates 
(Cultrera and Dalia, 2012). The rational devel-
opment of more targeted therapies is compli-
cated by the heterogeneity of DLBCL as well as 
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The epigenetic dysregulation of tumor suppressor genes is an important driver of human 
carcinogenesis. We have combined genome-wide DNA methylation analyses and gene 
expression profiling after pharmacological DNA demethylation with functional screening to 
identify novel tumor suppressors in diffuse large B cell lymphoma (DLBCL). We find that a 
CpG island in the promoter of the dual-specificity phosphatase DUSP4 is aberrantly methyl-
ated in nodal and extranodal DLBCL, irrespective of ABC or GCB subtype, resulting in loss 
of DUSP4 expression in 75% of >200 examined cases. The DUSP4 genomic locus is further 
deleted in up to 3% of aggressive B cell lymphomas, and the lack of DUSP4 is a negative 
prognostic factor in three independent cohorts of DLBCL patients. Ectopic expression of 
wild-type DUSP4, but not of a phosphatase-deficient mutant, dephosphorylates c-JUN  
N-terminal kinase (JNK) and induces apoptosis in DLBCL cells. Pharmacological or dominant-
negative JNK inhibition restricts DLBCL survival in vitro and in vivo and synergizes strongly 
with the Bruton’s tyrosine kinase inhibitor ibrutinib. Our results indicate that DLBCL cells 
depend on JNK signaling for survival. This finding provides a mechanistic basis for the 
clinical development of JNK inhibitors in DLBCL, ideally in synthetic lethal combinations 
with inhibitors of chronic active B cell receptor signaling.
© 2015 Schmid et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure . Integration of DNA methylation and RNA expression profiles identifies potential tumor suppressor genes in DLBCL. (A) The median 
methylation of CpG islands in promoter and regulatory regions was determined for 6 DLBCL cell lines (purple), 6 controls (tonsils and CD19+ B cells, light 
and dark blue), and 16 gastric lymphoma samples (MZL and DLBCL, light and dark green). Islands with a range in  values over all samples of at least 0.25 
were used for hierarchical clustering (metric = 1-Spearman correlation, linkage = complete). Pairs of low (MZL)- and high-grade (DLBCL) samples obtained 
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lymphoid tissue [MALT] type, 9 gastric DLBCL) and 6 
DLBCL cell lines to human Methylation450BeadChip arrays. 
Four tonsil and two CD19+ B cell samples served as normal 
controls. Unsupervised hierarchical clustering of all 28 sam-
ples revealed a promoter methylation signature that was shared 
by the majority of gastric lymphomas and DLBCL cell lines, but 
not the normal controls (Fig. 1 A). Gastric MZL and DLBCL 
exhibited largely indistinguishable methylation patterns, es-
pecially if taken sequentially from the same patient (Fig. 1 A). 
A comprehensive analysis integrating a published (Asmar 
et al., 2013) as well as a publicly accessible (Cancer Genome 
Atlas) dataset of nodal DLBCL with our gastric dataset re-
vealed a shared DLBCL methylation signature irrespective of 
anatomical location (Fig. 1 B). To assess which of the aber-
rantly methylated genes could be transcriptionally reactivated 
by global DNA demethylation, we performed RNA sequenc-
ing of DLBCL cell lines before and after treatment with the 
demethylating agent 5-aza-2-deoxycytidine in combination 
with the HDAC inhibitor 4-phenylbutyric acid (PBA) and of 
two human blood donor-derived B cell samples that had been 
activated in vitro by IgM and CD40 cross-linking. Principal 
component analysis revealed the segregation of the samples 
based on the experimental treatment they were subjected to 
(Fig. 1 C). We then integrated the information gleaned from 
the global DNA methylation and gene expression surveys to 
identify genes that (a) are re-expressed upon DNA demethyl-
ation, (b) are aberrantly methylated in the cell lines, and (c) are 
either expressed or not in normal B cells activated in vitro. Of 
the 900 genes identified by this approach (Fig. 1 D), 35 were 
found to be hypermethylated also in a majority of the 16 gas-
tric and 59 nodal lymphoma samples (Fig. 1 E). Several of these 
genes had previously been described to be epigenetically reg-
ulated in B cell lymphomas, i.e., CDKN1C (Li et al., 2002), 
KLF4 (Guan et al., 2010), and TLE-1 (Fraga et al., 2008).
We were able to obtain expression constructs for 30 of the 
35 genes of interest for the functional assessment of their 
tumor-suppressive properties. The ectopic expression of 8 of 
the 30 genes strongly and consistently reduced the viability 
of two DLBCL cells lines as assessed by metabolic activity 
assay and annexin V staining of apoptotic cells (Fig. 2, A and B). 
All eight genes thus likely represent epigenetically silenced 
tumor suppressor genes in DLBCL (see Fig. 2 C for their 
methylation status in the clinical samples and cell lines); of 
the coexistence of genetic lesions affecting multiple redun-
dant survival pathways. Genetic aberrations in DLBCL either 
exclusively affect GCB-DLBCL (deregulated c-Myc or Bcl-2 
expression, gain of function of the H3K27 methyltransferase 
EZH2) or ABC-DLBCL (A20 loss, gain of function of 
MYD88, CD79A/B, or CARD11, all of which promote the 
constitutive activation of the NF-B pathway) or are found in 
both major subtypes (inactivating mutations and deletions in 
the histone acetyltransferases CBP and p300 as well as the 
histone methyl transferase MLL2; Schneider et al., 2011; Shaffer 
et al., 2012; Pasqualucci and Dalla-Favera, 2014).
Aberrant changes of the DNA methylation landscape 
are a hallmark of cancer cells and have been linked to clinical 
aggressiveness and chemoresistance of DLBCL (Shaknovich 
et al., 2010; Clozel et al., 2013; De et al., 2013; Chambwe et al., 
2014). Examples of tumor suppressor genes known to be 
silenced by promoter hypermethylation in DLBCL include 
SMAD1, MGMT, CDKN2A, and the lamin A/C gene 
(Martinez-Delgado et al., 1997; Esteller et al., 2002; Agrelo 
et al., 2005; Clozel et al., 2013). We have shown in earlier 
studies that the epigenetic silencing of the tumor suppressor 
microRNAs miR-203 and miR-34a contribute to the trans-
formation of gastric MZL to DLBCL and to the deregulated 
expression of the hematopoietic oncoprotein FoxP1 (Craig 
et al., 2011a,b). Here, we have conducted a genome-wide 
analysis of the DNA methylome of gastric DLBCL and MZL 
and of nodal DLBCL samples and cell lines. The hypermeth-
ylated gene loci were further examined by RNA sequencing 
with respect to their reactivation upon experimental DNA 
demethylation. Aberrantly silenced genes were ectopically 
expressed in DLBCL cell lines and assessed for possible effects 
on cell survival. This unbiased approach uncovered a new 
tumor suppressor in DLBCL, the dual-specificity phosphatase 
DUSP4, and introduces the constitutively active JNK signal-
ing pathway as a promising new target in DLBCL treatment.
RESULTS
Genome-wide profiling of DNA methylation and gene 
expression reveals epigenetic silencing of putative tumor 
suppressor genes in gastric and nodal DLBCL
To generate a global DNA methylation profile of gastric B cell 
lymphoma, we hybridized DNA from 16 archived paraffin-
embedded lymphoma biopsies (7 MZL of mucosa-associated 
from the same patient are indicated (n = 3). (B) Hierarchical clustering based on CpG island methylation in promoter and regulatory regions of the samples 
shown in A, along with 6 additional B cell samples (blue) and 59 nodal DLBCL cases (light green). (C) Multidimensional scaling (MDS) plot highlighting  
the overall similarity in gene expression levels, as determined by RNA sequencing and principal component analysis, of the six indicated samples in two-
dimensional representation. The distances between samples represent the estimates of the coefficient of variation of expression between samples  
for the top 500 most variable genes. (D) Venn diagram of methylated and expressed genes as classified based on the following four outcomes (from left): 
(a) differentially expressed in DLBCL cell lines before and after 5-aza-2-deoxycytidine and PBA treatment, FDR of 5%; (b) highly expressed in activated  
B cells, according to a selected cut-off separating the two modes of the expression distribution, in log (counts per million); (c) methylated ( value >0.6) 
in at least two out of three ABC-DLBCL cell lines; (d) methylated ( value >0.6) in CD19+ B cells. Gene groups of interest are highlighted in yellow.  
(E) Methylation and expression data for 35 selected candidate genes (names indicated on the right) are shown. The yellow–black–blue color scale shows 
median CpG island  values for gastric lymphomas (n = 16), DLBCL cell lines (n = 6), normal controls (n = 12), and nodal DLBCL samples (n = 59); the 
green–gray–red color scale shows log (counts per million) expression values for activated B cells and DLBCL cell lines (n = 2; the results represent a  
limited number of repeats) before and after 5-aza-2-deoxycytidine and PBA treatment.
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The DUSP4 genomic locus is hypermethylated  
or deleted in nodal and extranodal DLBCL
We focused on the dual-specificity phosphatase DUSP4 in all 
subsequent experimental efforts because it showed the high-
est expression in normal activated B cells and was strongly re-
activated upon 5-aza-2-deoxycytidine and PBA treatment in 
U2932 cells (Fig. 1 E; note that the other investigated cell line, 
Oci-Ly10, carries a deletion in one of two DUSP4 alleles, 
which attenuates the ability of this cell line to up-regulate 
the eight, five encode transcription factors (CRY1, CASZ1, 
ZNF502, TEAD1, and ZFP28), and the remaining three 
encode proteins with enzymatic activity (the phosphatase 
DUSP4, the kinase PRKCH, and the phospholipase C 1 
PLCB1). None of the eight genes have been functionally 
linked to the pathogenesis of DLBCL or any other type of 
B cell lymphoma, although two have been implicated in other 
hematological malignancies (CRY1 in CLL; PLCB1 in myelo-
dysplastic syndrome).
Figure 2. Eight epigenetically silenced genes are proapoptotic in DLBCL cell lines. (A and B) Functional analysis was conducted of 30 candidate 
genes in U-2932 (A) and RC-K8 (B) cell lines. Cell viability and apoptosis were assessed 72 h after electroporation with the indicated expression plasmids 
by CellTiter-Blue assay and annexin V staining, respectively (top and bottom panels), and are represented relative to empty vector–transfected controls.  
A second round of experiments was performed with candidates that reduced the viability below 75% of controls in both cell lines (blue bars; mean + SEM 
of two independent experiments; the results represent a limited number of repeats). (C) Median  values were calculated for all probes corresponding to 
the regulatory and promoter regions of the eight genes with proapoptotic activity identified in A and B, as determined by methylation array for the indi-
cated samples (mean ± SEM). *, P < 0.05; **, P < 0.01; ***, P < 0.001, two-tailed Student’s t test.
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Figure 3. The DUSP4 promoter is hypermethylated in nodal and extranodal DLBCL, which correlates with lack of DUSP4 protein expression. 
(A) Bisulfite sequencing of 16 CpG dinucleotides in island 28 was performed for 11 DLBCL cell lines and 2 peripheral blood B cell samples and a set of 18 clini-
cal lymphoma and 3 tonsil samples. Closed and open circles represent methylated and unmethylated CpGs, respectively. Between two and five clones were 
sequenced per sample. The alignment of the DUSP4 promoter sequence of the indicated species was performed using ECR Browser and shows the high  
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conservation of CpG island 28 in other mammalian species relative to the human sequence (top left). (B) DUSP4 expression by the indicated lymphoma enti-
ties was assessed by IHC of a lymphoma tissue microarray. The graph shows percentage of DUSP4-positive cases (>30% positive cells) and DUSP4-negative 
cases (<30% positive cells) for the indicated lymphoma entities (top left). Representative micrographs show staining of a tonsillar GC (with insets) as well as 
DUSP4-positive and -negative DLBCL and CLL cases (bars, 50 µm; insets bars, 25 µm). CLL, n = 20; MZL, n = 54; FL, n = 48; MCL, n = 9; nodal DLBCL, n = 170; 
extranodal DLBCL, n = 87; transformed DLBCL, n = 9; and tonsils, n = 3. (C) The correlation of DUSP4 promoter methylation (assessed by bisulfite sequencing) 
with DUSP4 protein expression (determined by IHC) was plotted for 16 lymphoma cases. **, P < 0.01, calculated using Mann–Whitney test; horizontal lines 
indicate medians. (D) CD138+ plasma cells were isolated from 9-mo-old C57BL/6 mice. T cells and B cell subsets were sorted from splenocyte preparations 
based on CD3, B220, CD21, and CD23 expression according to the depicted sorting strategy. DUSP4 expression in the indicated subsets was analyzed by qRT-
PCR and depicted as mean + SEM. Plasma cells: two pools of three mice each; T cells: n = 2 individual mice (the results represent a limited number of re-
peats); spleen: n = 3 individual mice; IM, MZ, and FO: n = 5 individual mice. n.d., not detected; T, T cells; B, B cells; IM, immature splenic B cells (CD21low, 
CD23); MZ, marginal zone B cells (CD21high, CD23); FO, follicular B cells (CD21int, CD23+); PC, plasma cells. (E) DUSP4 copy number alterations were analyzed 
using the Progenetix database. The fractions of cases affected by deletions (of 100-Mb maximum length) targeting the DUSP4 locus are shown for the indi-
cated lymphoma entities. A representative ABC-DLBCL array CGH profile showing a focal DUSP4 deletion is shown in the left panel.
 
DUSP4 upon 5-aza-2-deoxycytidine and PBA treatment) 
and because the signaling pathways targeted by DUSP4 ap-
peared likely to contribute to DLBCL pathogenesis. To vali-
date our methylation array–based findings on a separate set of 
DLBCL samples using a different technical approach, we per-
formed bisulfite sequencing of the CpG island 28 upstream of 
the DUSP4 transcription start site (Waha et al., 2010). All 11 
examined cell lines and 10 of 13 primary nodal and extra-
nodal DLBCL patient biopsies exhibited widespread DUSP4 
promoter methylation, whereas normal B cells and tonsil sam-
ples were unmethylated (Fig. 3 A). Aberrant methylation 
of the DUSP4 locus is thus a unifying feature of DLBCL ir-
respective of the subtype and anatomical site of origin, but 
was not observed in CLL (Fig. 3 A). Preliminary data obtained 
by chromatin immunoprecipitation of various epigenetically 
modified histone variants followed by PCR-based amplifica-
tion of the DUSP4 CpG island 28 suggest that repressive his-
tone marks (H3K9me2, H3K27me3) are enriched and active 
histone marks (H3K9ac, H4ac) are underrepresented at the 
DUSP4 promoter in the DLBCL cell line SU-DHL16 rela-
tive to normal blood-derived B cells (not depicted). To ex-
amine whether promoter hypermethylation and repressive 
histone modifications at the DUSP4 promoter indeed result in 
loss of DUSP4 expression, we performed DUSP4-specific 
immunohistochemistry (IHC) on a B cell lymphoma tissue 
microarray featuring 397 cases that range in aggressiveness 
from indolent MZL of MALT type to primary nodal, extra-
nodal, and secondary transformed DLBCL; several tonsil sam-
ples were examined for comparison. DUSP4 expression was 
exclusively nuclear in all DUSP4-positive cells (Fig. 3 B). In-
dividual positive cells were detectable in the GCs of tonsils 
(Fig. 3 B). Interestingly, whereas 42% of MZL, 75% of CLL, 
40% of FLs, and 56% of mantle cell lymphomas (MCLs) were 
positive for DUSP4 expression, that rate dropped to 20–25% 
for high-grade transformed DLBCL originating from gastric 
MZLs, FLs, or CLL (Fig. 3 B). Primary nodal and extranodal 
DLBCL had similar low rates of DUSP4 positivity. Whereas 
DUSP4 expression rates were thus significantly different be-
tween aggressive and indolent lymphomas (P = 0.01), no sig-
nificant differences could be detected between the classified 
cases of ABC (26 of 83; 31%)- and GCB-type (11 of 33; 33%) 
nodal DLBCL. We further performed both DUSP4 IHC and 
bisulfite sequencing of 16 cases of DLBCL and CLL and in-
deed found a clear inverse association between DUSP4 ex-
pression and the extent of DUSP4 promoter methylation 
(Fig. 3 C). To examine in more detail which lymphocyte sub-
sets express DUSP4 under physiological conditions, we sorted 
CD138+ plasma cells from mouse bone marrow and various 
lymphocyte subsets from mouse spleen. Interestingly, expres-
sion of DUSP4 was limited to splenic follicular and immature 
B cells and was not found in plasma cells, splenic marginal 
zone B cells, or splenic T cells (Fig. 3 D).
We next examined whether the DUSP4 genomic locus 
is subject to recurrent deletion events. Of the 1,263 DLBCL 
samples for which comparative genomic hybridization data 
are available from a publicly accessible database of DNA copy 
number alterations (http://www.progenetix.org; Baudis and 
Cleary, 2001), 6.4% exhibited losses in the DUSP4 genomic 
locus, of which a few were highly focal (Fig. 3 E). The frac-
tions of other B cell lymphoma and leukemia entities with 
DUSP4 deletions ranged from 3% (CLL and FL) to 13.4% 
(MCL; Fig. 3 E). In conclusion, loss of DUSP4 expression is a 
common event in lymphomagenesis and can be attributed 
either to the relatively rare loss of the DUSP4 genomic locus or 
to its commonly observed epigenetic modification.
DUSP4 promoter hypermethylation  
represses DUSP4 expression
To experimentally assess whether DUSP4 promoter hypermeth-
ylation affects DUSP4 expression, we first examined DUSP4 
levels in blood-derived B cells from healthy human donors. 
Circulating human B cells with unmethylated DUSP4 pro-
moters (Fig. 3 A) did not express DUSP4 unless they were 
activated by IgM and/or CD40 cross-linking or treatment 
with the phorbol ester PMA (Fig. 4 A), an analogue of diacyl-
glycerol which stimulates protein kinase C–dependent B cell 
activation (Teixeira et al., 2003; Cagnol and Rivard, 2013). In 
contrast, DLBCL cell lines with hypermethylated promoters 
failed to optimally express DUSP4 even when treated with 
PMA, unless they had been subjected to prior treatment with 
5-aza-2-deoxycytidine in combination with the HDAC inhibi-
tor PBA (Fig. 4, B and C). Similarly, treatment with an IgM 
cross-linking antibody activated optimal DUSP4 expression in 
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Ectopic DUSP4 expression induces apoptosis  
in a phosphatase activity–dependent manner
To assess the effects of DUSP4 re-expression on DLBCL via-
bility in detail, five DLBCL cell lines were electroporated 
with a cDNA expression construct encoding DUSP4. Ecto-
pic expression of wild-type DUSP4 reduced cell viability and 
induced apoptotic cell death as assessed by CellTiter-Blue 
assay and annexin V staining (Fig. 5, A–C). This effect was de-
pendent on DUSP4 enzymatic activity, as ectopic expression 
of a point mutant (C280S) lacking phosphatase activity 
(Robinson et al., 2001) did not affect the viability of DLBCL 
cells (Fig. 5, A–C). In line with their shared, almost universal 
DUSP4 promoter methylation, GCB- and ABC-type DLBCL 
cell lines were equally susceptible to ectopic DUSP4 expres-
sion (Fig. 5, A–C; note that the RC-K8 subtype is controversial: 
DLBCL cells only after treatment with 5-aza-2-deoxycytidine/
PBA, and only if the examined cell line actually expressed 
surface IgM (sIgM; Fig. 4 B). This was the case for the cell 
line U-2932, but not RC-K8, which is sIg negative, or 
SU-DHL16, which expresses sIgG (Fig. 4 B). Interestingly, 
5-aza-2-deoxycytidine/PBA treatment not only efficiently 
demethylated the DUSP4 promoter and, in combination 
with PMA or anti-IgM, promoted DUSP4 expression, but 
also strongly reduced the viability of all examined DLBCL 
cell lines (Fig. 4, B–E). The combined results indicate that the 
widespread hypermethylation of the DUSP4 promoter in 
DLBCL indeed results in functional DUSP4 deficiency, which 
can only be overcome with the appropriate stimulus if the 
epigenetic repression is first relieved by DNA demethylation 
in combination with HDAC inhibition.
Figure 4. Combined DNA demethylation and HDAC inhibition relieves DUSP4 repression. (A) CD19+ peripheral blood B cells were stimulated with 
100 nM PMA, 10 µg/ml anti-IgM, and/or 500 ng/ml CD40L for the indicated times. DUSP4 expression was assessed by qRT-PCR (normalized to RPLPO). 
Data represent mean + SEM of two to four blood donors. (B) DUSP4 transcript levels were measured for the three indicated DLBCL cell lines after treat-
ment with 5 µM 5-aza-2-deoxycytidine, 3 mM PBA, 100 nM PMA, and 10 µg/ml anti-IgM alone or in the indicated combinations. Data represent means +  
SEM of at least three independent experiments. *, P < 0.05; **, P < 0.01, calculated using two-tailed Student’s t test. (C) DUSP4 protein expression was 
detected by immunoblotting for the two indicated DLBCL cell lines after treatment with 5 µM 5-aza-2-deoxycytidine, 3 mM PBA, and/or 100 nM PMA; 
representative Western blot images are shown together with densitometric ratios of DUSP4/-tubulin. Graphs represent mean + SEM of two independent 
experiments (the results represent a limited number of repeats). (D) The viability of DLBCL cell lines after treatment with 5-aza-2-deoxycytidine and PBA, 
alone or in the indicated combinations, was determined by colorimetric CellTiter-Blue assay. Data are representative of two independent experiments and 
are shown as mean + SEM (the results represent a limited number of repeats). (E) Bisulfite sequencing of CpG island 28 was performed for untreated  
U-2932 cells and U-2932 cells after treatment with 5-aza-2-deoxycytidine, either alone or in combination with PBA. Closed and open circles represent 
methylated and unmethylated CpGs, respectively. Three individual clones of one experiment were sequenced.
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dephosphorylated in ABC and GCB cell lines upon forced 
expression of wild-type DUSP4 (Fig. 6, B and C). ERK1/2 
phosphorylation increased upon ectopic DUSP4 expression 
in U-2932 cells, a finding which is in line with the docu-
mented negative regulation of ERK phosphorylation by ac-
tive JNK (Shen et al., 2003; Fey et al., 2012). Phosphatase-dead 
DUSP4 had only minor effects on JNK1/2 phosphorylation 
(Fig. 6, B and C). Ectopic DUSP4 expression affected the nu-
clear pool of JNK; immunofluorescence staining for phospho-
JNK revealed a significant reduction in nuclear staining 
intensity in cells that had been transfected with DUSP4 rela-
tive to empty vector–transfected cells (Fig. 6, D and E). More-
over, the expression of endogenous DUSP4 induced by the 
IgM/CD40-mediated activation of normal human B cells 
also correlated with dephosphorylation of JNK (Fig. 6, F and G). 
The combined results suggest that JNK1/2 is the only direct 
MAP kinase target of DUSP4 in (normal and malignant) 
B cells. We next attempted to perform IHC for phosphory-
lated JNK on our lymphoma tissue array, which was compli-
cated by the fact that the fixation procedures used for most 
spotted samples were incompatible with p-JNK detection. Nev-
ertheless, a subset of 37 samples that allowed for both p-JNK 
although lumped with GCB-type DLBCL here based on 
Lenz et al. [2007], cells may actually be of the ABC subtype 
[Schmitz et al., 2012]). In contrast, progression through the 
cell cycle was not impaired upon ectopic DUSP4 expression, 
as the fraction of cells in the S, G1, and G2 phases of the cell 
cycle did not differ in any of the cell lines, as determined 
by EdU incorporation assay in conjunction with propidium 
iodide (PI) staining (Fig. 5 D). In summary, DUSP4 has pro-
apoptotic activity in DLBCL cell lines of both subtypes, and 
its epigenetic silencing likely provides a significant growth 
advantage to DLBCL cells.
JNK is the preferred and biologically relevant  
MAP kinase target of DUSP4 in DLBCL
DUSP4 has been described to dephosphorylate MAP kinases 
of the JNK, p38, and ERK families. We found JNK1/2 and 
two p38 family members to be expressed and constitutively 
phosphorylated at steady-state in 11 examined cell lines irre-
spective of the GCB/ABC subtype, whereas ERK1/2 is 
phosphorylated only in ABC-DLBCL lines (Fig. 6 A). Only 
JNK1 and JNK2, but not p38 or ERK1/2, were consistently 
Figure 5. Ectopic DUSP4 expression decreases the viability of DLBCL cell lines by inducing apoptosis. (A) The viability of five different DLBCL cell 
lines was assessed 72 h after transfection with DUSP4 wt or DUSP4 p.C280S mutant constructs, relative to empty vector–transfected cells (control). Data 
represent means + SEM of at least three independent experiments. (B and C) Apoptosis of the same DLBCL cell lines as shown in A was assessed 72 h 
after transfection with DUSP4 wt or DUSP4 p.C280S mutant constructs relative to empty vector–transfected cells (control). A representative annexin V 
flow cytometry histogram of three independent experiments is shown in B. Data in C represent mean + SEM of at least three independent experiments 
per cell line. (A and C) *, P < 0.05; **, P < 0.01; ***, P < 0.001, calculated using two-tailed Student’s t test. (D) Edu-PI staining of SU-DHL16 cells was per-
formed 72 h after transfection. Representative flow cytometry dot plots of three independent experiments are shown. The numbers indicate the percent-
age of live cells in the G1, S, and G2-M phases of the cell cycle, respectively.
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Figure . JNK is the preferred and biologically relevant MAP kinase target of DUSP4 in DLBCL. (A) Steady-state ERK, p38, and JNK activity was 
assessed in a set of six ABC- and five GCB-DLBCL cell lines by phospho-specific Western blotting. Overall protein expression of the respective kinases and 
of tubulin is shown for comparison. One representative of two independent experiments is shown. (B) U-2932 and SU-DHL16 cells were transfected with 
empty vector (control) or DUSP4 wt or DUSP4 p.C280S mutant constructs. MAP kinase activity was analyzed by phospho-specific Western blotting 72 h 
after transfection. p-JNK/total JNK, n = 4; p-p38/total 38 and p-ERK/total ERK, n = 2. (C) The densitometric ratio of phospho-MAPK relative to the total 
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MAPK is shown for four (JNK, top) and two (p38, middle; ERK, bottom; results represent a limited number of repeats) independent experiments. SEM is 
shown. (D) Immunofluorescence microscopy images of p-JNK (green) and DAPI (blue) were obtained 72 h after transfection of SU-DHL16 cells with con-
trol (empty vector) or DUSP4 wt construct. One representative picture per condition of four independent experiments is shown. (E) Mean nuclear p-JNK 
intensity of at least 30 nuclei per experimental condition was quantified using Cell Profiler software. Mean and SEM of four independent experiments are 
shown. (F) CD19+ peripheral blood B cells were activated with 10 µg/ml anti-IgM and 500 ng/ml CD40L for the indicated times, followed by analysis of 
endogenous DUSP4 protein expression and JNK phosphorylation by Western blotting. (G) Densitometric ratios of p-JNK/total JNK (left) and DUSP4/-
tubulin (right) of two independent experiments were determined for samples as shown in F (results represent a limited number of repeats). SEM is shown. 
(H) 37 clinical cases of DLBCL were stained for DUSP4 protein expression and p-JNK by IHC. Representative micrograph images of two DLBCL cases are 
shown in the left panel. The relationship of DUSP4 and p-JNK expression is shown in a contingency table (right). The p-value was calculated by 2 test  
(P = 0.152, n = 37). Bars: (D) 25 µm; (H) 50 µm. (I) The viability of U-2932 and RC-K8 cells was determined by CellTiter-Blue assay after 72 h of treatment 
with 50 µM SP600125 (JNK inhibitor), SB203580 (p38 inhibitor), or FR180204 (ERK inhibitor) relative to DMSO-treated cells. Means + SEM of three  
independent experiments are shown. (C, E, and I) *, P < 0.05; **, P < 0.01; ***, P < 0.001, calculated by two-tailed Student’s t test.
 
and DUSP4 staining revealed the mutually exclusive expression 
of the two markers (Fig. 6 H), suggesting that the JNK signal-
ing pathway is active in the absence of DUSP4.
To functionally assess which MAP kinases are not only 
active but also required for DLBCL survival, we next exam-
ined the effects of inhibitors blocking JNK, p38, or ERK1/2. 
Only a JNK inhibitor, but not inhibitors of ERK1/2 or 
p38, had measurable effects on U-2932 and RC-K8 viability 
(Fig. 6 I). The combined results suggest that DLBCL cells de-
pend critically on active JNK signaling and that the growth 
advantage conferred by DUSP4 deficiency is caused by unre-
stricted (nuclear) JNK activity.
Pharmacological and genetic inhibition of JNK  
blocks DLBCL growth in vitro and in vivo
To examine the growth-inhibitory effects of JNK inhibition 
in more detail, we performed dose–response measurements 
with the ATP-competitive JNK inhibitor SP600125 in vari-
ous DLBCL cell lines. Concentrations of SP600125 that 
strongly reduced c-JUN phosphorylation were also effective 
at reducing DLBCL viability and inducing apoptosis (Fig. 7, 
A–D). Additional inhibitors of JNK with a different mode 
of action, i.e., covalent irreversible binding to both JNK 
isoforms in the case of IN-8, and competition with scaffold 
protein binding in the case of BI-87G3, also exhibited dose-
dependent growth inhibitory effects in all examined cell lines 
(Fig. 7, E and F). A genetic approach using dominant-negative 
constructs of JNK1 and -2 confirmed that the activity of both 
JNKs is critical for the survival of all examined DLBCL cell 
lines (Fig. 7 G).
We next investigated the effects of SP600125 in a xeno-
graft model of DLBCL using the ABC-type cell line U-2932. 
SP600125 was administered every other day at 30 mg/kg 
body weight either starting 1 d after subcutaneous lymphoma 
cell implantation or once palpable tumors had formed. Both 
treatments significantly reduced tumor volumes as measured 
over time, as well as the tumor weight at the study endpoint 
(Fig. 7, H–J); adverse effects of the treatment on overall animal 
health were not observed in the time frame of the experi-
ment. The combined results suggest that JNK inhibition re-
duces DLBCL viability and induces apoptosis in vitro and 
impairs xenograft growth in vivo.
JNK inhibition synergizes with Bruton’s tyrosine  
kinase (BTK) inhibition to limit DLBCL growth
Ibrutinib is a novel inhibitor of BTK that has proven to be 
effective in ABC-DLBCL with chronic active BCR signal-
ing in various preclinical combination treatments (Mathews 
Griner et al., 2014). To examine whether simultaneous JNK 
and BTK inhibition synergizes to kill DLBCL cells, we con-
ducted single and combination treatments with SP600125 
and ibrutinib. Ibrutinib treatment alone was insufficient to kill 
any of our DLBCL cell lines at concentrations up to 1 µM 
(Fig. 8 A). However, the addition of ibrutinib, even at very 
low doses of 1–10 nM, strongly boosted the efficacy of 
SP600125 in two ABC-DLBCL cell lines (Fig. 8, B and C). 
This effect was not seen in the GCB cell line SU-DHL16 
(Fig. 8 D) or in an ABC-DLBCL cell line in which the BCR 
signaling pathway is constitutively active as the result of a 
CARD11 mutation (Oci-Ly3; Fig. 8 E). In those cell lines 
where ibrutinib augmented the effects of JNK inhibition, 
the two treatments were clearly synergistic, as determined by 
Chalice matrix analyses and the isobologram method (Fig. 8, 
F and G). In summary, our data indicate that JNK inhibitors 
should be considered for assessment as single agents in clinical 
trials for both subtypes of DLBCL and might be especially 
promising in combination with ibrutinib in ABC-DLBCL.
Lack of DUSP4 expression is a negative  
prognostic factor in ABC- and GCB-DLBCL
To address whether the lack of DUSP4 expression would 
affect DLBCL patient survival, we analyzed three large cohorts 
of patients that had received standard chemotherapy consist-
ing of cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (CHOP), with or without the addition of rituximab 
(R-CHOP), and had previously been subjected to microarray-
based gene expression profiling (Lenz et al., 2008; Visco 
et al., 2012). All three cohorts were subdivided into DUSP4low 
(lowest quartile of DUSP4 expression) and DUSP4high groups 
(comprising the remaining three quartiles) based on their 
DUSP4 transcript levels, and their overall survival probability 
was plotted over time. In all three cohorts, high DUSP4 gene 
expression was associated with a superior survival probability 
relative to the corresponding DUSP4low group, independent 
of the treatment regimen (Fig. 9, A–C). The largest cohort, 
which had received R-CHOP treatment (Visco et al., 2012), 
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Figure 7. Pharmacological and genetic inhibition of JNK blocks DLBCL growth in vitro and in vivo. (A) The viability of the DLBCL cell lines indicated 
was determined by CellTiter-Blue assay after 72 h of treatment with increasing concentrations of the JNK inhibitor SP600125 relative to DMSO-treated cells. 
Means + SEM for two to four independent experiments per cell line are shown. (B) A Western blot analysis of phosphorylated c-JUN (representative of three 
independent experiments), total c-JUN, and TFIIH expression (loading control) after 24 h of treatment with the indicated concentrations of SP600125 is 
shown. (C) Densitometric ratios of phospho–c-JUN/TFIIH and total c-JUN/TFIIH were calculated for the samples shown in B. (D) Apoptosis of RIVA and U-2932 
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cells was assessed after 72 h of treatment with 30 µM SP600125, as measured by annexin V staining. Mean and SEM of three independent experiments are 
shown. (E and F) The viability of DLBCL cell lines was assessed after 72 h of treatment with the indicated concentrations of the JNK inhibitors BI-87G3 and 
JNK-IN-8. Mean + SEM of at least three independent experiments is shown. (G) The cell viability and apoptosis of the two indicated DLBCL cell lines was de-
termined by CellTiter-Blue assay and annexin V staining 72 h after transfection with dominant-negative JNK constructs (1.5 µg pCDNA3-JNK1a1(apf) + 1.5 µg 
pcDNA3-JNK2a2(apf)) and are presented as percentage values relative to empty vector–transfected cells. Mean + SEM of three independent experiments are 
shown. (D and G) *, P < 0.05; **, P < 0.01, calculated using two-tailed Student’s t test. (H–J) NOD/SCID/IL2R/ mice were subcutaneously inoculated in both 
flanks with 107 U-2932 cells. Mice were treated every other day with 30 mg/kg SP600125 i.p. starting on day 1 after transplantation (blue) or when tumors 
were palpable (day 11, green) as shown in the diagram in H. Tumor growth in I was measured as a function of tumor volume, which is represented as means 
± SEM. Vehicle control, n = 9 mice (18 individual tumors); treatment from start, n = 6 mice (12 tumors); treatment when palpable, n = 11 mice (22 tumors). 
The top and bottom panels in J show tumor weights and tumor volumes at the study endpoint. **, P < 0.01; ***, P < 0.001, one-way analysis of variance with 
Bonferroni’s post-test. Pooled data from two experiments are shown in I and J.
 
was further stratified into ABC- and GCB-type DLBCL 
patients based on overall gene expression signatures and sub-
jected to subtype-specific survival analysis. As reported previ-
ously (Visco et al., 2012), both subtypes differed strongly in 
terms of their overall survival probability, with GCB-DLBCL 
patients surviving longer than their ABC-DLBCL counter-
parts (compare Fig. 9, D and E). In each subtype, high DUSP4 
expression was associated with significantly superior survival 
(Fig. 9, D and E), indicating that the expression of DUSP4 
serves as a positive prognostic factor for survival prediction in 
DLBCL, irrespective of subtype and therapeutic regimen. The 
results confirm and extend our experimental data and dem-
onstrate that DUSP4 is not only a likely tumor suppressor in 
DLBCL, but also has prognostic value for survival prediction 
independent of subtype.
DISCUSSION
In this study, we have performed a genome-wide DNA meth-
ylome analysis of DLBCL cell lines and primary patient ma-
terial followed by an unbiased functional assessment of the 
tumor-suppressive properties of the 30 top epigenetically 
silenced candidates. Several unexpected observations were 
made in the course of our methylome analyses. First, although 
several thousand aberrantly methylated genes were identified 
in our gastric set of lymphoma cases, the methylation patterns 
were very similar in low-grade MZL of MALT and high-grade 
gastric DLBCL. This was particularly striking given the vast 
differences in the aggressiveness and clinical prognosis of the 
two lymphoma entities. Three pairs of consecutively isolated 
low- and high-grade samples from the same patient confirmed 
this general trend; no obvious differences were detected within 
the pairs. In fact, two of the three even clustered together on 
very short branches of the dendrogram tree, documenting 
their highly similar DNA methylation patterns. Aberrant pro-
moter hypermethylation thus appears to constitute an early 
rather than late event in gastric lymphomagenesis. A detailed 
comparison of the promoter-associated CpG island methyla-
tion profiles of our own gastric lymphoma set with those of 
nodal DLBCL cases further revealed the striking similarity of 
nodal and extranodal cases with respect to their methylomes. 
With the exception of a handful of cases in every sample set 
that did not share the general methylation patterns of all others 
and instead clustered with the unmethylated controls, all nodal 
and gastric cases exhibited a highly consistent methylation 
profile. This observation suggests that both types share a com-
mon pathogenetic mechanism irrespective of the affected site 
and the underlying cause of the disease, which is likely infec-
tious in the gastric form (Isaacson and Du, 2004) and largely 
unknown in the nodal form.
The methylation of the promoter regions of most of the 
genes that we identified by array could be verified using bi-
sulfite sequencing; false-positive hits were rare. However, not 
all of the hypermethylated genes could be reactivated by 
global pharmacological demethylation, indicating that these 
are not expressed by DLBCL cells, at least under in vitro cul-
ture conditions. Of the 30 hypermethylated genes that were 
reactivated upon DNA demethylation and therefore selected 
for individual functional assessment, only eight were found to 
affect cell viability. The dysregulation of one of the eight, the 
dual-specificity phosphatase DUSP4, proved to be particu-
larly widespread and biologically meaningful in the extra-
nodal as well as nodal forms of the disease, warranting further 
in depth analyses of the affected signaling pathways. The biol-
ogy of DUSP4, which dephosphorylates both phospho- 
serine/threonine and phospho-tyrosine residues on its MAP 
kinase substrates, is poorly understood in the context of can-
cer. The silencing of DUSP4 by promoter hypermethylation 
was reported in the past for certain forms of secondary glio-
blastomas and anaplastic astrocytomas (Waha et al., 2010), as 
well as basal-like breast cancer (BLBC), where low DUSP4 
transcript levels after neoadjuvant chemotherapy have been 
linked to MEK–ERK pathway activation and chemotherapy 
resistance (Balko et al., 2012). Follow-up analyses have attrib-
uted the effects of DUSP4 loss in BLBC to the maintenance 
of a cancer stem cell population, which is dependent on ac-
tive JNK and ERK signaling and MAP kinase–dependent 
IL-6 as well as IL-8 production (Balko et al., 2013). DUSP4 
promoter methylation of the CpG island 344 was also re-
cently reported as part of a broader methylation signature for 
several types of lymphoma, including Burkitt lymphoma, FL, 
and ABC-DLBCL (Bethge et al., 2014). Although limited by 
the rather small number of analyzed cases, the study found 
a trend toward higher methylation frequencies in ABC- 
compared with GCB-DLBCL (Bethge et al., 2014). We report 
here that methylation of the CpG island 28 in the DUSP4 
promoter region serves as a reliable indicator of the lack of 
DUSP4 expression in various subtypes, i.e., nodal and extra-
nodal, ABC and GCB, of DLBCL: the region is methylated in 
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marks are enriched on CpG island 28 of the DUSP4 pro-
moter in DLBCL cells (unpublished data).
In accordance with the aberrant epigenetic silencing of 
the DUSP4 genomic locus in DLBCL, we found that DUSP4 
expression levels can be used for survival prognostication. The 
lack of DUSP4 expression was a clear negative prognostic 
factor in multiple large cohorts of DLBCL, irrespective of the 
applied treatment regimen (CHOP vs. R-CHOP) and sub-
type of DLBCL analyzed. The combined results of the regula-
tion of DUSP4 expression by DNA methylation and histone 
modification, and its value as a survival factor, together imply 
all cell lines lacking DUSP4 expression, and there is a clear 
inverse correlation of DUSP4 expression and methylation 
status in all analyzed clinical cases. The opposite is seen in 
clinical cases of CLL, which largely exhibit unmethylated 
DUSP4 promoters and express high levels of the protein. Ex-
posure to 5-aza-2-deoxycytidine, especially in combination 
with HDAC inhibition, clearly reduces DUSP4 CpG island 
28 methylation and promotes DUSP4 re-expression. The de-
pendence of the phenotype on HDAC inhibition is explained 
by our preliminary data showing that active histone marks 
(such as H3K9ac and H4ac) are lost and repressive histone 
Figure 8. The JNK inhibitor SP0025  
synergizes with ibrutinib in killing ABC-DLBCL 
cell lines. (A) The viability of DLBCL cell lines was 
determined by CellTiter-Blue assay after 72 h of 
treatment with the indicated concentrations of 
the BTK inhibitor ibrutinib and calculated relative 
to DMSO-treated cells. Means ± SEM for two to 
four independent experiments per cell line are 
shown. (B–G) The viability of the indicated DLBCL 
cell lines was assessed after 72 h of treatment 
with increasing concentrations of the JNK inhibi-
tor SP600125 and the BTK inhibitor ibrutinib, 
either alone or in combination, relative to DMSO-
treated cells. In F, Chalice Analyzer inhibition 
matrices are shown for combination responses to 
SP600125 and ibrutinib of the indicated cell lines. 
In G, isobolograms of viability data demonstrating 
drug synergy are shown for the indicated cell 
lines. The results presented in G were compiled 
from B, C, and F. In B, C, F, and G, data from at 
least three and up to four independent experi-
ments are shown; in D and E, data from two  
independent experiments (results represent a 
limited number of repeats) are shown. Results  
in A–E are presented as means ± SEM.
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stem cell maintenance and therapy resistance (Balko et al., 2013). 
JNK inhibition not only promoted apoptosis of DLBCL cell 
lines upon in vitro treatment, but also effectively delayed 
tumor growth and reduced tumor burden in a xenograft model 
of DLBCL. The effects of JNK inhibition were not only pre-
ventive, but also therapeutic in our hands, as established tu-
mors also grew more slowly under systemic JNK inhibitor 
treatment. JNK inhibition represents a largely untested strat-
egy in hematopoietic malignancies, and only sporadic studies 
exist in the literature. In vitro studies suggest that JNK signal-
ing may be active and may contribute to tumor cell prolifera-
tion in certain cases of MCL and classical Hodgkin lymphoma 
(Wang et al., 2009; Leventaki et al., 2014); JNK signaling is 
also known to be active in TNF-secreting acute myelogenous 
leukemia cells (Volk et al., 2014). Consequently, inhibition of 
JNK signaling impaired the growth of Hodgkin and Reed-
Sternberg cells and of MCL cell lines and acute myelogenous 
leukemia cells in vitro, either as single treatment or in combi-
nation (Wang et al., 2009; Boukhiar et al., 2013; Leventaki 
et al., 2014; Volk et al., 2014). In vivo efficacy has further been 
shown for JNK inhibition in xenografts of immature B cell 
that DNA methyltransferase inhibitors and HDAC inhibitors 
should be considered for the treatment of DLBCL patients 
with DUSP4-negative tumors, especially given that compounds 
belonging to both classes of drugs are approved and/or in 
clinical development for the treatment of other hematological 
malignancies (Dhanak and Jackson, 2014).
In line with a putative tumor suppressor activity of DUSP4 
in DLBCL, we found that ectopic expression of the wild-type 
protein, but not the C280S point mutant lacking phosphatase 
activity, induced apoptosis in all examined DLBCL cell lines. 
Apoptosis occurred as a direct result of DUSP4 expression 
rather than as a secondary consequence of cell cycle arrest 
and was mediated by the DUSP4-dependent inactivation of 
JNK signaling. In accordance with these findings, the phar-
macological or dominant-negative inhibition of the two JNKs, 
but not of ERK or of p38, phenocopied the cytotoxicity of 
forced DUSP4 re-expression, suggesting that the JNK signal-
ing pathway is more critical than the other two to the survival 
of DLBCL cell lines. Our data thus differ from the proposed 
mechanism of DUSP4 silencing in BLBC, where the MEK–
ERK pathway has predominantly been implicated in cancer 
Figure . The level of DUSP4 expression correlates with overall survival of DLBCL patients. (A–C) Kaplan–Meier curves displaying overall survival 
of three DLBCL patient cohorts (GEO accession nos. GSE31312 and GSE10846) treated with R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, 
vincristine, and prednisone; A and B) or CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone; C) as a function of DUSP4 mRNA 
expression are shown. (D and E) Kaplan–Meier curves displaying overall survival probability based on DUSP4 mRNA expression in ABC (D) and GCB (E) 
subsets of DLBCL patients are shown. (A–E) All cohorts were subdivided based on low (first quartile) and high (second to fourth quartile) DUSP4 expres-
sion. The log-rank test was used for statistical analysis: *, P < 0.05; **, P < 0.01; ***, P < 0.001. Visco et al. (2012), n = 470; ABC subtype, n = 226; GCB 
subtype, n = 242; Lenz et al. (2008) R-CHOP, n = 233; Lenz et al. (2008) CHOP, n = 181. The Lenz et al. (2008) dataset was analyzed using R software, and 
the Visco et al. (2012) data were analyzed using the R2 microarray analysis and visualization platform (http://r2.amc.nl).
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plasmid DNA using the Amaxa Nucleofector II device (Lonza). Cells were 
harvested 72 h after transfection for protein extraction or subjected to func-
tional analysis. For drug treatments, cells were seeded at a density of 0.4 × 
106/ml with the respective drug concentration and analyzed for cell viability 
or apoptosis 72 h later. For viability assays, 50 µl of cell suspension was trans-
ferred into 96-well plates containing 50 µl fresh medium in triplicates 72 h 
after treatment/electroporation. 20 µl CellTiter-Blue reagent (Promega) was 
added, and plates were incubated for 4 h at 37°C, 5% CO2 in a humidified 
atmosphere. Viability was subsequently assessed by measuring fluorescence 
at 560Ex/590Em using a SpectraMax M5 microplate reader (Molecular 
Devices). For drug combination experiments, percent viability/inhibition 
was calculated in Excel (Microsoft) relative to DMSO-treated wells. Format-
ted data were analyzed by Chalice Analyzer (Horizon) to generate inhibition 
matrices and to assess the presence and extent of synergism by isobologram 
analysis. The quantification of apoptosis by an Annexin V detection kit (BD) 
was performed according to the manufacturer’s instructions. Flow cytometry 
was performed on a Cyan ADP 9 instrument (Beckman Coulter) and ana-
lyzed using FlowJo software. For cell cycle analysis, the Click-IT EdU cy-
tometry assay kit (Invitrogen) was used in combination with PI staining. Cells 
were incubated with 10 µM EdU for 90 min, followed by fixation, perme-
abilization, and intracellular staining according to the manufacturer’s instruc-
tions. 100 µg/ml RNase A and 20 µg/ml PI were added for 30 min before 
flow cytometric analysis.
Animal experimentation. U-2932 cells were injected subcutaneously into 
both flanks of 6–8-wk-old NOD/SCID/IL2R/ mice (The Jackson Lab-
oratory). SP600125 was dissolved in 10% DMSO, 2% Tween 80, and 2% 
PEG600 in PBS. 1 d after tumor cell injection or when palpable tumors had 
formed (40 mm3), mice were i.p. injected with 30 mg/kg SP600125 or ve-
hicle every other day. Tumor volumes were measured using the formula (a2 × 
b)/2, where a is the shorter and b the longer tumor dimension. All animal 
experiments were reviewed and approved by the Zürich Cantonal Veterinary 
Office (licenses 147/2011 and 224/2014).
Global methylation profiling and RNA sequencing. Genomic DNA 
was isolated from archived FFPE biopsies of seven low-grade MZLs of 
MALT, nine high-grade gastric DLBCL cases, and four reactive tonsil samples 
using the RecoverAll Total Nucleic Acid Isolation kit for FFPE material (Life 
Technologies). In addition, genomic DNA was extracted from healthy pe-
ripheral blood B cells of two donors and six nodal DLBCL cell lines using 
the NucleoSpin tissue kit (MACHEREY-NAGEL). Global methylation pro-
filing of these samples was performed on 450K Infinium arrays (Illumina) at 
the USC Epigenome Center core facility, Los Angeles. For RNA sequencing, 
CD19-positive peripheral blood B cells were activated with 10 µg/ml anti-
IgM (SouthernBiotech) and 500 ng/ml CD40L (eBioscience) for 44 h. 
ABC-DLBCL cell lines (U-2932 and Oci-Ly10) were treated with 5 µM 
5-aza-2-deoxycytidine (Sigma-Aldrich) for 3 d, followed by 16 h with 
3 mM PBA (Sigma-Aldrich). RNA from the B cells and cell lines was iso-
lated using the miRNeasy Mini kit (QIAGEN). RNA quality was assessed by 
Bioanalyzer 2100 followed by library preparation using the TruSeq RNA 
Sample Prep kit v2 (Illumina). Sequencing was subsequently performed on 
the HiSeq 2000 instrument (Illumina). All data are accessible through Array 
Express: RNA-seq, E-MTAB-2925; 450K methylation data, E-MTAB-2926. 
Methylation data for nodal DLBCL cases and additional CD19+ B cells 
(controls) were retrieved from GEO accession nos. GSE37365 and GSE35069 
and the Cancer Genome Atlas.
Processing of DNA methylation and RNA sequencing data. R ver-
sion 3.0.2 and minfi version 1.8.9 were used to process the HumanMethyl-
ation450 array data. Raw 450K array data were normalized by applying the 
preprocess Illumina function using bg.correct = TRUE and normalize = 
“controls.” Probes were filtered according to suggestions from Price et al. 
(2013), eliminating probes that map to multiple locations in the human ge-
nome or overlap known polymorphic sites in their target CpG. After filter-
ing, we focused only on probes in regions near annotated CpG islands, again 
lymphomas, glioblastomas, and colorectal cancer, also with-
out evidence of adverse effects (Jemaà et al., 2012; Matsuda 
et al., 2012).
To test whether our approach of JNK inhibition may be 
combined with existing therapeutic strategies to achieve syn-
thetic lethality, we conducted coinhibition experiments with 
ibrutinib, which is approved and marketed for high-risk CLL 
and refractory MCL and is currently in phase 2 trials for 
ABC-DLBCL. Ibrutinib clearly synergized with JNK inhibition 
to reduce the viability and induce apoptosis of certain DLBCL 
cell lines but not others. Interestingly, only ABC-DLBCL 
with an unmutated BCR signaling pathway, but not GCB-
DLBCL or a CARD11 mutant ABC-DLBCL cell line, re-
sponded to the SP600125/ibrutinib combination. This result 
is in line with a critical role for chronic active BCR signaling 
in ABC, but not GCB-DLBCL survival (Davis et al., 2010), 
and the general observation that ibrutinib efficacy is limited 
to ABC-DLBCL with an unmutated BCR signaling pathway 
leading to constitutive oncogenic IB kinase and NF-B ac-
tivity (Ceribelli et al., 2014).
In summary, by applying an approach from bedside to 
bench and back to preclinical models, we have identified a 
novel pathogenetic mechanism in DLBCL that relies on the 
epigenetic silencing of the DUSP4 promoter, a widespread 
phenomenon in both extranodal and nodal cases. DUSP4 de-
ficiency gives rise to a constitutively active JNK signaling 
pathway, which can in turn be targeted pharmacologically to 
reduce tumor cell survival and prevent tumor progression 
in vitro and in vivo. Our results provide a mechanistic basis for 
the clinical development of JNK inhibitors for the treatment 
of DLBCL, particularly in a synthetically lethal combination 
with novel therapies targeting chronic active BCR signaling.
MATERIALS AND METHODS
Patient samples and cell culture. For whole-genome methylation analy-
sis and bisulfite sequencing, archived patient material of gastric low-grade 
MZL of MALT, nodal, extranodal, and transformed DLBCL, CLL, and reac-
tive tonsils was drawn from the surgical pathology files of the Institute of Pa-
thology at the Cantonal Hospital St. Gallen and from the files of the Institute 
of Pathology, University Hospital Basel. Diagnosis was established according 
to the classification system of the World Health Organization (WHO) on 
formalin-fixed, paraffin-embedded (FFPE) tissue. All data were blinded to 
guarantee patient protection. All procedures were in agreement with the 
guidelines for use of human material in research issued by the Ethics Com-
mittee of the Cantonal Hospital St. Gallen and the Ethical Committee of 
North-Western Switzerland. The DLBCL cell lines used were SU-DHL4, 
SU-DHL6, SU-DHL10, SU-DHL16, and RC-K8 of GCB-DLBCL subtype 
and U-2932, Oci-Ly3, Oci-Ly10, SU-DHL2, SU-DHL5, and RIVA of 
ABC-DLBCL, as well as SU-DHL7 (unclassified). Cell lines were maintained 
at 37°C, 5% CO2 in a humidified atmosphere in RPMI or IMDM (RIVA 
and Oci-Ly10) supplemented with 10% (Oci-Ly10, RIVA, SU-DHL2, and 
SU-DHL5) or 20% heat-inactivated FBS and antibiotics. CD19-positive B cells 
were isolated from buffy coats of healthy volunteer blood donors obtained from 
the blood donation center Zürich (ZHBSD) by immunomagnetic sorting and 
cultured in RPMI, 10% FCS, 2 mM l-glutamine, 50 µM -mercaptoethanol, 
2 ng/ml hIL-4 (eBioscience), and antibiotics.
Transient transfection of DLBCL cell lines, pharmacological treat-
ments and viability, cell cycle, and apoptosis assays. For the purpose 
of ectopic gene expression, 106 DLBCL cells were nucleoporated with 3 µg 
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fwd, 5-CCAGCTCTGGAGAAACTGCTG-3; and rev, 5-CAGCA-
GCTGGCACCTTATTGG-3; mouse Dusp4 fwd, 5-ATCCCCGTC-
GAAGACAACC-3; and rev, 5-CGCCCTCGACAGTCCTTTAC-3; 
and mouse Gapdh fwd, 5-GACATTGTTGCCATCAACGACC-3; and 
rev, 5-CCCGTTGATGACCAGCTTCC-3.
Western blotting, IHC, and immunofluorescence microscopy. Pro-
tein extracts were made in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM 
sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) 
supplemented with 2 mM sodium orthovanadate, 15 mM sodium pyrophos-
phate, 10 mM sodium fluoride, and 1× complete protease inhibitor cocktail 
(Roche). Protein concentrations were determined using BCA assay (Thermo 
Fisher Scientific), and equal amounts were separated by SDS-PAGE followed 
by transfer onto nitrocellulose membranes. Membranes were probed with 
antibodies against DUSP4 (D9A5), phospho-p38 Thr180/Tyr182 (D3F9), 
total p38 (D13E1), phospho-ERK1/2 Thr202/Tyr204 (D13.14.4E), total 
ERK (137F5), phospho-SAPK/JNK Thr183/Tyr185 (81E11), and total 
SAPK/JNK (56G8; all from Cell Signaling Technology), as well as phospho–
c-JUN Ser63 (Y172; EMD Millipore), total c-JUN (5B1; Abcam), tubulin 
(DM1A; Sigma-Aldrich), and TFIIH p89 (s-19; Santa Cruz Biotechnology, 
Inc.). If applicable, blots were first incubated with phospho-specific antibodies 
and then stripped in 10 ml of 10% SDS, 6.25 ml of 0.5 M Tris-HCl, 
pH 6.8, 33.75 ml H2O, and 400 µl -mercaptoethanol for 30 min at 50°C, 
followed by incubation with the respective phosphorylation-independent anti-
bodies. Quantification was performed using ImageJ 1.48v software (National 
Institutes of Health).
Tissue microarrays with 170 primary nodal DLBCLs, 87 extranodal 
DLBCLs (stomach and testis), 9 DLBCLs transformed from low-grade 
lymphomas, 54 MZLs of MALT, 48 FLs, and 20 small lymphocytic B cell 
lymphomas (SLLs)/CLL, as well as 9 MCLs were constructed as described 
previously (Muenst et al., 2010). For the cases studied on conventional slides 
(i.e., 12 nodal DLBCLs, 5 extranodal DLBCLs, 2 transformed DLBCLs, 3 
CLL/SLLs, and 2 MZLs, as well as 3 normal tonsils), blotting-based quantitative 
protein expression data were available, thus allowing validation of the immuno-
histochemical analysis. The cases were classified as GCB or non-GCB–like 
(ABC) DLBCL applying the Tally algorithm (Meyer et al., 2011). DUSP4 
staining was established by application of the primary antibody sc-10797 
from Santa Cruz Biotechnology, Inc. (best working dilution 1:20) to tonsils, 
breast, and colon cancer, whereas pJNK staining was established by applica-
tion of the primary antibody 4668 from Cell Signaling Technology (best 
working dilution 1:50). IHC was performed on an automated immuno-
stainer (Benchmark; Ventana/Roche). Antigen retrieval was achieved by mild 
cell conditioning (CC1 from Ventana/Roche) treatment for 16 min in the 
case of DUSP4 and for 92 min in the case of pJNK. Primary antibody incu-
bation was performed for 32 min in the case of DUSP4 and for 120 min in 
the case of pJNK before visualization (chromogen ultraview universal diami-
nobenzidine from Ventana/Roche). Finally, slides were counterstained with 
hematoxylin and bluing reagent from Ventana/Roche. The proportion of 
positively staining tumor cells (steps: 0, 1, 5, 10, 15, and 20%, followed by 10% 
steps) as well as the subcellular localization (membranous, cytoplasmic, and 
nuclear) were all taken into consideration. pJNK showed exclusive nuclear 
staining, whereas DUSP4 intensively stained nuclei but also showed some 
weak cytoplasmic background staining. For both DUSP4 and pJNK, only 
nuclear signals were considered. 30% cut-off scores were applied. For phospho-
JNK–specific immunofluorescence microscopy, SU-DHL16 cells were 
electroporated as described above, cytospun onto glass slides, fixed for 15 min 
in 4% formaldehyde in PBS, blocked for 60 min at room temperature in PBS, 
1% goat serum, and 0.3% Triton X-100, and stained overnight at 4°C with 
anti–p-JNK (4668 from Cell Signaling Technology; 1:400) in PBS, 1% BSA, 
and 0.3% Triton X-100, followed by detection with a Alexa Fluor 488– 
coupled goat anti–rabbit secondary antibody (Life Technologies; 1:400; 1 h at 
room temperature). Nuclei were counterstained with DAPI and covered 
with fluorescent mounting medium (S3023; Dako). Cells were imaged on a 
DM RB microscope (Leica) equipped with a DFC 360 FX camera (Leica). 
Images were taken with an HCX PLAPO 63×/1.4-0.6 oil immersion objective 
using the reannotated tables from Price et al. (2013) to associate CpG islands 
with transcriptional units. We then calculated summaries at the CpG island 
level by taking the median of  values for the probes in those regions (tran-
scription start sites, first exons, 5UTR, and regulatory elements) for each 
sample. CpG islands were filtered to only those that had a range in  values 
(consensus methylation estimate) over all samples of at least 0.25. Hierarchical 
clustering was conducted using the fastcluster version 1.1.13 using 1-Spearman 
correlation distance metric and “complete” linkage. RNA-seq reads were 
quality-checked with fastqc, which computes various quality metrics for the 
raw reads. RNA-seq FASTQ files were mapped to the hg19 reference human 
genome using tophat2 (Kim et al., 2013), and reads were counted according 
to Entrez Gene annotation using the summarizeOverlaps function in the 
GenomicAlignments Bioconductor package (Lawrence et al., 2013). Statistical 
analysis of differential expression was conducted with the edgeR package (Anders 
et al., 2013) using a design matrix that gives the pairing Oci-Ly10 treated with 
5-aza/PBA and untreated; U2932 treated with 5-aza/PBA and untreated.
Cell sorting and immunomagnetic cell separation. CD19+ B cells were 
isolated from peripheral blood of healthy blood donors using the MACS 
human CD19 microbeads (Miltenyi Biotec). For isolation of CD138+ plasma 
cells from mouse bone marrow, the CD138 plasma cell isolation kit (Miltenyi 
Biotec) was used according to the manufacturer’s protocol. For isolation of 
T cells and B cell subsets from mouse spleens, single cell suspensions were 
prepared, incubated with Fc-block (Miltenyi Biotec), and stained with B220-
PB (BioLegend), CD21/35-APC (BD), CD23-PE-Cy7 (BioLegend), and 
CD3-PE (eBioscience). Cell sorting was performed at the University of Zürich 
Flow Cytometer Core Facility on an Aria III instrument (BD).
Kinase inhibitors, plasmid constructs, and site-directed mutagenesis. 
The JNK inhibitors SP600125 and JNK-IN-8 and the BTK inhibitor Ibruti-
nib were obtained from Selleckchem. The JNK inhibitor BI-87G3 as well as 
inhibitors of p38 (SB203580) and ERK1/2 (FR180204) were purchased from 
Sigma-Aldrich. Overexpression constructs used in the functional screen were 
obtained from Origene in the pCMV6 vector or from Biocat in the pTCN or 
pCMV-Sport6 backbones. Plasmids expressing a dominant-negative form of 
JNK (Gupta et al., 1996) were obtained from R.J. Davis (University of Massa-
chusetts Medical School, Worcester, MA) through Addgene (plasmid number 
13761, 13846). A phosphatase-inactive mutant of DUSP4, in which cysteine 
280 in the wild-type DUSP4 sequence (pTCN-BC002671, Origene) is re-
placed by a serine, was generated using GENEART site-directed mutagenesis 
(Invitrogen) as described previously (Robinson et al., 2001).
Bisulfite sequencing. Genomic DNA was isolated from FFPE tissue or 
fresh material using the RecoverAll total RNA Isolation kit (Life Technolo-
gies) or the NucleoSpin tissue kit, respectively. 1 µg gDNA was converted 
with sodium bisulfite as previously reported (Frommer et al., 1992) using 
the EpiTect bisulfite kit (QIAGEN). Bisulfite-converted DNA was ampli-
fied with primers specific for the CpG island 28 in the DUSP4 promoter 
(fwd, 5-TGGATTTGATTGTTATTTATTGGTTA-3; rev, 5-CAAAA-
CATTTCTAAAAAAAACCTCTC-3) and subcloned into the pGEM-T 
vector. The methylation status was subsequently assessed by sequencing the 
amplified DUSP4 promoter region and analyzed using the quantification 
tool for methylation analysis (QUMA; Kumaki et al., 2008).
Real-time PCR. RNA was extracted using the NucleoSpin RNA II kit 
(MACHEREY-NAGEL) or the RNeasy micro kit (QIAGEN) in the case 
of FACS-sorted samples. 1 µg total RNA was reverse transcribed using 
SuperScriptIII reverse transcription (Invitrogen). For quantitative RT-PCR 
(qRT-PCR), LightCycler 480 Cyber Green Master I (Roche) was used fol-
lowed by analysis on a LightCycler 480 instrument. Samples were measured 
in duplicates. For all primer pairs, the efficiency was calculated by perform-
ing dilution series experiments. Target mRNA abundance was subsequently 
calculated relative to human RPLP0 or mouse Gapdh. The primers used 
were the following: human DUSP4 fwd, 5-TGCATCCCAGTGGAA-
GATAA-3; and rev, 5-GCAGTCCTTCACGGCATC-3; human RPLP0 
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